Merck & Co. Inc. is planning $12bn in capital investments over the next five years to add capacity for key growth-drivers in oncology, vaccines and animal health, the company said during a Feb. 2 earnings call.
Merck reported $35.4bn in full-year 2017 pharmaceutical sales, up 1% from the prior year. The company's PD-1 inhibitor Keytruda (pembrolizumab)...








